Colin Alexander Espie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Colin Alexander Espie has a total of 410 co-authors. Here are the top co-authors by number of shared publications:
- Simon David Kyle
John Radcliffe Hospital, NIHR Oxford Biomedical Research Centre, Oxford, UK
22 shared publications - Annemarie I. Luik
Trimbos-institute: Trimbos-instituut
11 shared publications - Bjørn Bjorvatn
Department of Global Public Health and Primary Care University of Bergen Bergen Norway
9 shared publications - Luigi De Gennaro
Department of Psychology Sapienza University of Rome Rome Italy
9 shared publications - Yun Kwok Wing
Li Chiu Kong Family Sleep Assessment Unit, Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong SAR, China
9 shared publications - Giuseppe Plazzi
Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy; IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy
8 shared publications
Latest Publications
- Open Access
- 27 August 2026
- Published by Taylor & Francis in Behavioral Sleep Medicine
- p. 1-12
“Why don’t They Seek Help?” A Qualitative Study of Barriers and Motivators to Insomnia Treatment Among Youth
Insomnia is a common sleep problem in youth, with prevalence estimates up to 37% (Chan et al., 2020; Li et al., 2018). If left untreated, insomnia symptoms may persist and negatively affect individ...
- 27 August 2026
- Published by Taylor & Francis in Behavioral Sleep Medicine
- p. 1-12
Open Access“Why don’t They Seek Help?” A Qualitative Study of Barriers and Motivators to Insomnia Treatment Among Youth
Insomnia is a common sleep problem in youth, with prevalence estimates up to 37% (Chan et al., 2020; Li et al., 2018). If left untreated, insomnia symptoms may persist and negatively affect individ...
- Open Access
- 31 May 2026
- Published by Wiley in Journal of Sleep Research
- Vol. 35 (5) , e70371
Association of Prodromal Parkinson's Disease‐Like Features in Long COVID With Dream‐Enactment Behaviours
Emerging evidence links COVID‐19 to the predisposition of Parkinson's disease (PD). However, the relationship between long COVID and prodromal PD‐like features remains unclear, particularly in long COVID participants with dream‐enactment behaviours (DEBs) that may be suggestive of possible REM sleep behaviour disorder. This study aimed to quantify the burden of prodromal PD‐like features in long COVID. This online survey (May–Nov 2021) across 16 countries/regions included 11,261 participants. Data on demographics, COVID‐19 diagnosis, long COVID symptoms, sleep features and other typical prodromal PD‐like features were collected. The likelihood ratio (LR) of prodromal PD was calculated as a proxy for each participant's overall burden of prodromal PD‐like features, based on the 2019 Movement Disorder Society research criteria. Participants with long COVID ( n = 1155) exhibited more symptoms suggestive of prodromal PD‐like features, including DEBs, olfactory dysfunctions, constipation, excessive daytime sleepiness, postural dizziness, depression with/without anxiety, urinary dysfunctions, cognitive impairment and a higher LR of prodromal PD when compared to non‐COVID‐19 participants and COVID‐19 recoverees. Long COVID was associated with a 73% higher burden of potential prodromal PD‐like features (adjusted odds ratio [aOR] = 1.73, 95% confidence interval [CI] = 1.57–1.90). Among those with long COVID, emergence or exacerbation of post‐infection DEBs further increased this burden by 38% (aOR = 1.38, 95% CI = 1.19–1.60). Our study suggested that long COVID is associated with an increased burden of prodromal PD‐like features, which appears to be further enhanced with DEBs.
- 31 May 2026
- Published by Wiley in Journal of Sleep Research
- Vol. 35 (5) , e70371
Open AccessAssociation of Prodromal Parkinson's Disease‐Like Features in Long COVID With Dream‐Enactment Behaviours
Emerging evidence links COVID‐19 to the predisposition of Parkinson's disease (PD). However, the relationship between long COVID and prodromal PD‐like features remains unclear, particularly in long COVID participants with dream‐enactment behaviours (DEBs) that may be suggestive of possible REM sleep behaviour disorder. This study aimed to quantify the burden of prodromal PD‐like features in long COVID. This online survey (May–Nov 2021) across 16 countries/regions included 11,261 participants. Data on demographics, COVID‐19 diagnosis, long COVID symptoms, sleep features and other typical prodromal PD‐like features were collected. The likelihood ratio (LR) of prodromal PD was calculated as a proxy for each participant's overall burden of prodromal PD‐like features, based on the 2019 Movement Disorder Society research criteria. Participants with long COVID ( n = 1155) exhibited more symptoms suggestive of prodromal PD‐like features, including DEBs, olfactory dysfunctions, constipation, excessive daytime sleepiness, postural dizziness, depression with/without anxiety, urinary dysfunctions, cognitive impairment and a higher LR of prodromal PD when compared to non‐COVID‐19 participants and COVID‐19 recoverees. Long COVID was associated with a 73% higher burden of potential prodromal PD‐like features (adjusted odds ratio [aOR] = 1.73, 95% confidence interval [CI] = 1.57–1.90). Among those with long COVID, emergence or exacerbation of post‐infection DEBs further increased this burden by 38% (aOR = 1.38, 95% CI = 1.19–1.60). Our study suggested that long COVID is associated with an increased burden of prodromal PD‐like features, which appears to be further enhanced with DEBs.
- Open Access
Insights from nine nights of self-applied, low-density sleep EEG during sleep restriction therapy: a proof-of-concept evaluation
Objectives: Self-applied, low-density EEG offers opportunities to examine sleep in the home environment, yet its feasibility during behavioural sleep interventions remains unexplored. This pilot study aimed to evaluate the feasibility and acceptability of a self-applied, low-density EEG device during sleep restriction therapy (SRT) and explore effects on sleep and affect. Methods: Seventeen adults with insomnia and depressive symptoms completed a 2-week baseline and 4 weeks of SRT. The primary outcome was the proportion of expected EEG recordings completed and scoreable. Secondary outcomes included clinical measures, sleep continuity (sleep diary, actigraphy), sleep architecture (low-density EEG for 9 nights), power spectral density, and affect. Data were analysed with linear mixed models. Cohen's d and 95% confidence intervals were reported. Results: Feasibility was demonstrated (92% of expected EEG nights completed). SRT was associated with reductions in insomnia severity, depressive symptoms, negative affect, and increases in positive affect. Robust improvements were observed across treatment in sleep continuity (SOL, WASO, SE) from diary, which were paralleled by actigraphy. EEG revealed reduced TIB, TST, N1, N2, REM sleep, and REM latency during week one. Reductions in EEG-derived TIB and N1 sleep were maintained at night 28. There were no reliable differences for spectral or spindle measures. Conclusions: These findings suggest that self-applied, low-density EEG during SRT is feasible, acceptable, and may capture sleep changes during treatment. They highlight the potential for multi-night monitoring of sleep interventions at home and elucidating mechanisms underlying therapeutic change.
Open AccessInsights from nine nights of self-applied, low-density sleep EEG during sleep restriction therapy: a proof-of-concept evaluation
Objectives: Self-applied, low-density EEG offers opportunities to examine sleep in the home environment, yet its feasibility during behavioural sleep interventions remains unexplored. This pilot study aimed to evaluate the feasibility and acceptability of a self-applied, low-density EEG device during sleep restriction therapy (SRT) and explore effects on sleep and affect. Methods: Seventeen adults with insomnia and depressive symptoms completed a 2-week baseline and 4 weeks of SRT. The primary outcome was the proportion of expected EEG recordings completed and scoreable. Secondary outcomes included clinical measures, sleep continuity (sleep diary, actigraphy), sleep architecture (low-density EEG for 9 nights), power spectral density, and affect. Data were analysed with linear mixed models. Cohen's d and 95% confidence intervals were reported. Results: Feasibility was demonstrated (92% of expected EEG nights completed). SRT was associated with reductions in insomnia severity, depressive symptoms, negative affect, and increases in positive affect. Robust improvements were observed across treatment in sleep continuity (SOL, WASO, SE) from diary, which were paralleled by actigraphy. EEG revealed reduced TIB, TST, N1, N2, REM sleep, and REM latency during week one. Reductions in EEG-derived TIB and N1 sleep were maintained at night 28. There were no reliable differences for spectral or spindle measures. Conclusions: These findings suggest that self-applied, low-density EEG during SRT is feasible, acceptable, and may capture sleep changes during treatment. They highlight the potential for multi-night monitoring of sleep interventions at home and elucidating mechanisms underlying therapeutic change.
- Open Access
- 15 February 2026
- Published by Wiley in Journal of Sleep Research
- Vol. 35 (5) , e70306
Sleep Improvement for Metabolic Health: A Feasibility Trial of a Digital Sleep Treatment in People With Insomnia and Non‐Diabetic Hyperglycaemia
Insomnia may play a causal role in type 2 diabetes (T2D). Addressing insomnia through cognitive behavioural therapy (CBTi) in people with non‐diabetic hyperglycaemia could potentially reduce the risk of progression to T2D. To inform a future randomised trial, we performed a feasibility study of digital CBT (dCBTi) in individuals at increased risk of T2D. Participants were identified from 10 primary care practices in the UK and given access to dCBTi. Outcomes were evaluated at baseline (Week‐0) and post‐treatment (Week‐11). Primary feasibility outcomes were ability to recruit and treatment engagement. We also quantified within‐group mean change (95% CI) in insomnia severity (Insomnia Severity Index), health‐related quality of life (EQ‐5D‐3L), depression (Center for Epidemiologic Studies Depression Scale), chronotype (reduced Morningness‐Eveningness Questionnaire), sleep (7‐day actigraphy and diary), continuous glucose monitoring (7‐days) and fasting blood metabolites (insulin, lipids, glucose and C‐reactive protein). The recruitment target was 20. Of 242 people completing screening, 36 were eligible and 24 were enrolled (age 65.5 ± 12.4 years, 70.8% female). Twenty‐three (96%) completed post‐intervention assessments. Treatment engagement was excellent (83.3% completed ≥ 4 sessions). The intervention was associated with a large reduction in insomnia severity [−4.7 (95% CI: −6.2 to −3.2), d = −1.4] and medium reduction in depressive symptoms [−2.7 (95% CI: −5.1 to −0.2), d = −0.5]. Sleep diary parameters tended to show greater improvement following intervention relative to actigraphy. There was evidence of a reduction in serum lactate, glycerol and triglycerides but no clear change in glucose or insulin. Results suggest a full trial is likely feasible and that people with NDH find the intervention acceptable and beneficial. Trial Registration: This trial was prospectively registered on the UKs clinical study registry, the ISRCTN (ISRCTN19682964, https://doi.org/10.1186/ISRCTN19682964 )
- 15 February 2026
- Published by Wiley in Journal of Sleep Research
- Vol. 35 (5) , e70306
Open AccessSleep Improvement for Metabolic Health: A Feasibility Trial of a Digital Sleep Treatment in People With Insomnia and Non‐Diabetic Hyperglycaemia
Insomnia may play a causal role in type 2 diabetes (T2D). Addressing insomnia through cognitive behavioural therapy (CBTi) in people with non‐diabetic hyperglycaemia could potentially reduce the risk of progression to T2D. To inform a future randomised trial, we performed a feasibility study of digital CBT (dCBTi) in individuals at increased risk of T2D. Participants were identified from 10 primary care practices in the UK and given access to dCBTi. Outcomes were evaluated at baseline (Week‐0) and post‐treatment (Week‐11). Primary feasibility outcomes were ability to recruit and treatment engagement. We also quantified within‐group mean change (95% CI) in insomnia severity (Insomnia Severity Index), health‐related quality of life (EQ‐5D‐3L), depression (Center for Epidemiologic Studies Depression Scale), chronotype (reduced Morningness‐Eveningness Questionnaire), sleep (7‐day actigraphy and diary), continuous glucose monitoring (7‐days) and fasting blood metabolites (insulin, lipids, glucose and C‐reactive protein). The recruitment target was 20. Of 242 people completing screening, 36 were eligible and 24 were enrolled (age 65.5 ± 12.4 years, 70.8% female). Twenty‐three (96%) completed post‐intervention assessments. Treatment engagement was excellent (83.3% completed ≥ 4 sessions). The intervention was associated with a large reduction in insomnia severity [−4.7 (95% CI: −6.2 to −3.2), d = −1.4] and medium reduction in depressive symptoms [−2.7 (95% CI: −5.1 to −0.2), d = −0.5]. Sleep diary parameters tended to show greater improvement following intervention relative to actigraphy. There was evidence of a reduction in serum lactate, glycerol and triglycerides but no clear change in glucose or insulin. Results suggest a full trial is likely feasible and that people with NDH find the intervention acceptable and beneficial. Trial Registration: This trial was prospectively registered on the UKs clinical study registry, the ISRCTN (ISRCTN19682964, https://doi.org/10.1186/ISRCTN19682964 )
- Open Access
- 1 February 2026
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 30 (17) , 1-26
The clinical and cost-effectiveness of improving sleep via carer delivered strategies in people with dementia: the DREAMS START parallel multi-centre RCT
Background: Sleep disturbances are common and distressing for people with dementia and their family carers and can lead to carers having interrupted sleep, low mood and care breakdown. Medication can have harmful side effects and is generally ineffective. Non-pharmacological interventions should be first-line treatments, yet until now there have not been effective treatments. Objectives: To establish whether Dementia RElAted Manual for Sleep; STrAtegies for RelaTives (DREAMS START), a multicomponent intervention, reduced sleep disturbance in people with dementia living at home at 8 months compared with National Health Service treatment (treatment as usual). Design and methods: We conducted a two-arm, multicentre, parallel-arm, superiority randomised controlled trial with masked outcome assessment. Participants were randomised (1 : 1 ratio) to DREAMS START intervention plus treatment as usual or treatment as usual alone. Analyses were intention to treat. We conducted a mixed-method process evaluation with additional substudies: one exploring how United Kingdom-based South Asians experience sleep disturbance and dementia, and one exploring the interaction of sleep, dementia and long-term conditions. Settings and participants: We recruited dyads of people with dementia and sleep disturbance living at home and family carers from 12 National Health Service trusts and the Join Dementia Research service in England. Interventions: DREAMS START is a six-session, multicomponent, manualised intervention delivered to family carers of people with dementia who implement strategies to improve their relatives’ sleep. It is delivered face to face or remotely by non-clinically trained graduates weekly or fortnightly and incorporates information about sleep and dementia, promotes de-arousal at night, adaptive stimulus control (e.g. bedtime routine maintenance), daytime behavioural activation, increasing access to light, improving carer sleep and making a tailored action plan. Main outcome measures: The primary outcome was sleep disturbance measured using the Sleep Disorders Inventory at 8 months. Results: Between February 2021 and March 2023, 377 dyads were randomly assigned, 189 to treatment as usual and 188 to DREAMS START plus treatment as usual. Mean age of participants with dementia was 79.4 years (standard deviation 9.0), and 206 (55%) were women. Mean Sleep Disorders Inventory score at 8 months was lower in the intervention versus treatment-as-usual arm [15.16 (standard deviation 12.77), n = 159, vs. 20.34 (16.67), n = 163]; adjusted difference in means [−4.70 (95% confidence interval −7.65 to −1.74); p = 0.002]. Seventeen (9%) people with dementia in the intervention and 17 (9%) in the control arm died during the trial; deaths were unrelated to the intervention. The mean incremental difference in health and care costs incorporating wider costs was £116 less per dyad (95% confidence interval −£5769 to £5536) for DREAMS START compared to treatment as usual. There was a 78% probability that DREAMS START is cost-effective compared to treatment as usual at a £20,000 decision threshold with no significant difference in quality of life. Conclusion: DREAMS START plus treatment as usual is clinically effective in reducing sleep disturbance in people living at home with dementia at 8 months, demonstrating sustained effectiveness beyond intervention delivery. DREAMS START is likely to be cost-effective, and delivery by non-clinically trained graduates increases potential for National Health Service implementation at scale. Limitations: We relied upon family carers’ proxy and self-reported outcomes, with intervention participants potentially more invested and optimistic, increasing risk of bias. Additionally, based on our feasibility randomised controlled trial, we did not include actigraphy or another direct measure of sleep and activity. Future work: Studies should explore the longer-term effect of DREAMS START (we are following up participants at 2 years), and there should be an implementation study considering delivery and scaling up DREAMS START in real-world healthcare settings. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR128761.
- 1 February 2026
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 30 (17) , 1-26
Open AccessThe clinical and cost-effectiveness of improving sleep via carer delivered strategies in people with dementia: the DREAMS START parallel multi-centre RCT
Background: Sleep disturbances are common and distressing for people with dementia and their family carers and can lead to carers having interrupted sleep, low mood and care breakdown. Medication can have harmful side effects and is generally ineffective. Non-pharmacological interventions should be first-line treatments, yet until now there have not been effective treatments. Objectives: To establish whether Dementia RElAted Manual for Sleep; STrAtegies for RelaTives (DREAMS START), a multicomponent intervention, reduced sleep disturbance in people with dementia living at home at 8 months compared with National Health Service treatment (treatment as usual). Design and methods: We conducted a two-arm, multicentre, parallel-arm, superiority randomised controlled trial with masked outcome assessment. Participants were randomised (1 : 1 ratio) to DREAMS START intervention plus treatment as usual or treatment as usual alone. Analyses were intention to treat. We conducted a mixed-method process evaluation with additional substudies: one exploring how United Kingdom-based South Asians experience sleep disturbance and dementia, and one exploring the interaction of sleep, dementia and long-term conditions. Settings and participants: We recruited dyads of people with dementia and sleep disturbance living at home and family carers from 12 National Health Service trusts and the Join Dementia Research service in England. Interventions: DREAMS START is a six-session, multicomponent, manualised intervention delivered to family carers of people with dementia who implement strategies to improve their relatives’ sleep. It is delivered face to face or remotely by non-clinically trained graduates weekly or fortnightly and incorporates information about sleep and dementia, promotes de-arousal at night, adaptive stimulus control (e.g. bedtime routine maintenance), daytime behavioural activation, increasing access to light, improving carer sleep and making a tailored action plan. Main outcome measures: The primary outcome was sleep disturbance measured using the Sleep Disorders Inventory at 8 months. Results: Between February 2021 and March 2023, 377 dyads were randomly assigned, 189 to treatment as usual and 188 to DREAMS START plus treatment as usual. Mean age of participants with dementia was 79.4 years (standard deviation 9.0), and 206 (55%) were women. Mean Sleep Disorders Inventory score at 8 months was lower in the intervention versus treatment-as-usual arm [15.16 (standard deviation 12.77), n = 159, vs. 20.34 (16.67), n = 163]; adjusted difference in means [−4.70 (95% confidence interval −7.65 to −1.74); p = 0.002]. Seventeen (9%) people with dementia in the intervention and 17 (9%) in the control arm died during the trial; deaths were unrelated to the intervention. The mean incremental difference in health and care costs incorporating wider costs was £116 less per dyad (95% confidence interval −£5769 to £5536) for DREAMS START compared to treatment as usual. There was a 78% probability that DREAMS START is cost-effective compared to treatment as usual at a £20,000 decision threshold with no significant difference in quality of life. Conclusion: DREAMS START plus treatment as usual is clinically effective in reducing sleep disturbance in people living at home with dementia at 8 months, demonstrating sustained effectiveness beyond intervention delivery. DREAMS START is likely to be cost-effective, and delivery by non-clinically trained graduates increases potential for National Health Service implementation at scale. Limitations: We relied upon family carers’ proxy and self-reported outcomes, with intervention participants potentially more invested and optimistic, increasing risk of bias. Additionally, based on our feasibility randomised controlled trial, we did not include actigraphy or another direct measure of sleep and activity. Future work: Studies should explore the longer-term effect of DREAMS START (we are following up participants at 2 years), and there should be an implementation study considering delivery and scaling up DREAMS START in real-world healthcare settings. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR128761.
- Open Access
- 4 December 2025
- Published by JMIR Publications Inc. in JMIR Mental Health
- Vol. 12, e84323
The Effectiveness of Digital Cognitive Behavioral Therapy to Treat Insomnia Disorder in US Adults: Nationwide Decentralized Randomized Controlled Trial
Background: Cognitive behavioral therapy (CBT) is recommended as the first-line treatment for insomnia; however, few patients have access to it. A new class of Food and Drug Administration (FDA)–regulated digital CBT treatments has the potential to address this unmet need. These treatments are ordered or prescribed by health care providers and are fully automated, delivering CBT directly to patients without human coaches. This trial builds upon promising earlier digital cognitive behavioral therapy for insomnia (CBT-I) research by using a decentralized design to recruit a sample with greater representation of the US general population, including individuals from lower socioeconomic status groups who often face greater barriers to care. Objective: This decentralized trial evaluated the effectiveness of a fully automated digital CBT-I program (SleepioRx) for treating insomnia disorder compared with online sleep hygiene education (SHE) in a sample of participants recruited from across the United States. Methods: A decentralized, parallel-group randomized controlled trial was conducted between November 2022 and August 2023. Participants were recruited nationally from across the United States, and a total of 336 adults aged 22 and older, diagnosed with the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) insomnia disorder via structured clinical interview, were allocated 1:1 to either digital CBT-I (SleepioRx) or online SHE. The primary end points were insomnia severity, assessed using the Insomnia Severity Index (ISI), and sleep diary measures of sleep onset latency (SOL) and wake after sleep onset (WASO) at 10 weeks, with follow-up assessments at 16 and 24 weeks postrandomization. Results: Compared with SHE, SleepioRx showed statistically and clinically significant improvements on the ISI at posttreatment (10 weeks; Cohen d=0.60, P<.001), with effects sustained at follow-up (16 weeks; d=0.65, P<.001; and 24 weeks, d=0.77, P<.001). SleepioRx led to significant reductions in WASO at all time points (10 weeks, P=.003; 16 and 24 weeks, P<.001); however, effects on SOL were not statistically significant at an adjusted α (10 weeks, P=.01; 16 weeks, P=.07; 24 weeks, P=.27). SleepioRx participants had 2.5 times (odds ratio 2.52; P<.001, 99% CI 1.33-4.75) and 5.8 times (odds ratio 5.78; P<.001, 99% CI 2.11-15.84) greater odds of response and remission at week 10, respectively, with statistically and clinically significant differences in rates sustained at follow-up assessments (P<.001). SleepioRx also demonstrated sustained improvements in secondary sleep and broader mental health outcomes. Conclusions: The results of this trial demonstrate the effectiveness of digital CBT-I (SleepioRx) for treating insomnia, with gains sustained at 6 months, and support the FDA authorization of SleepioRx for the treatment of insomnia disorder. These findings underscore the potential of a new class of FDA-authorized, fully automated digital treatments to provide first-line, guideline-recommended CBT at scale. Efforts should now focus on expanding access to these evidence-based treatments. Trial Registration: ClinicalTrials.gov NCT05541055; https://clinicaltrials.gov/ct2/show/NCT05541055
- 4 December 2025
- Published by JMIR Publications Inc. in JMIR Mental Health
- Vol. 12, e84323
Open AccessThe Effectiveness of Digital Cognitive Behavioral Therapy to Treat Insomnia Disorder in US Adults: Nationwide Decentralized Randomized Controlled Trial
Background: Cognitive behavioral therapy (CBT) is recommended as the first-line treatment for insomnia; however, few patients have access to it. A new class of Food and Drug Administration (FDA)–regulated digital CBT treatments has the potential to address this unmet need. These treatments are ordered or prescribed by health care providers and are fully automated, delivering CBT directly to patients without human coaches. This trial builds upon promising earlier digital cognitive behavioral therapy for insomnia (CBT-I) research by using a decentralized design to recruit a sample with greater representation of the US general population, including individuals from lower socioeconomic status groups who often face greater barriers to care. Objective: This decentralized trial evaluated the effectiveness of a fully automated digital CBT-I program (SleepioRx) for treating insomnia disorder compared with online sleep hygiene education (SHE) in a sample of participants recruited from across the United States. Methods: A decentralized, parallel-group randomized controlled trial was conducted between November 2022 and August 2023. Participants were recruited nationally from across the United States, and a total of 336 adults aged 22 and older, diagnosed with the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) insomnia disorder via structured clinical interview, were allocated 1:1 to either digital CBT-I (SleepioRx) or online SHE. The primary end points were insomnia severity, assessed using the Insomnia Severity Index (ISI), and sleep diary measures of sleep onset latency (SOL) and wake after sleep onset (WASO) at 10 weeks, with follow-up assessments at 16 and 24 weeks postrandomization. Results: Compared with SHE, SleepioRx showed statistically and clinically significant improvements on the ISI at posttreatment (10 weeks; Cohen d=0.60, P<.001), with effects sustained at follow-up (16 weeks; d=0.65, P<.001; and 24 weeks, d=0.77, P<.001). SleepioRx led to significant reductions in WASO at all time points (10 weeks, P=.003; 16 and 24 weeks, P<.001); however, effects on SOL were not statistically significant at an adjusted α (10 weeks, P=.01; 16 weeks, P=.07; 24 weeks, P=.27). SleepioRx participants had 2.5 times (odds ratio 2.52; P<.001, 99% CI 1.33-4.75) and 5.8 times (odds ratio 5.78; P<.001, 99% CI 2.11-15.84) greater odds of response and remission at week 10, respectively, with statistically and clinically significant differences in rates sustained at follow-up assessments (P<.001). SleepioRx also demonstrated sustained improvements in secondary sleep and broader mental health outcomes. Conclusions: The results of this trial demonstrate the effectiveness of digital CBT-I (SleepioRx) for treating insomnia, with gains sustained at 6 months, and support the FDA authorization of SleepioRx for the treatment of insomnia disorder. These findings underscore the potential of a new class of FDA-authorized, fully automated digital treatments to provide first-line, guideline-recommended CBT at scale. Efforts should now focus on expanding access to these evidence-based treatments. Trial Registration: ClinicalTrials.gov NCT05541055; https://clinicaltrials.gov/ct2/show/NCT05541055
- Open Access
Sleep and circadian health in the UK Biobank: Report on the 2023 sleep questionnaire enhancement
Study Objectives: Our study introduced the 2023 UK Biobank sleep questionnaire and described variation in sleep health dimensions and prevalence of disordered sleep. Methods: A questionnaire comprising validated measures and bespoke items was developed to capture key self-reported domains of sleep health and symptoms of sleep disorders. We quantified cohort prevalence of operationally defined sleep disorders and assessed patterning of sleep health dimensions across key sociodemographic and clinically relevant variables. Results: 327,752 individuals were invited of whom 185,056 (56.5%) completed at least one module and were included in the analysis. Respondents were predominately from a White ethnic background (96.8%), had a mean age of 69.9 (SD, 7.5) years, 57.9% were female, and 25.5% were in employment. Compared to non-respondents, respondents were more likely to be female, tended to be better educated, healthier, and exhibit lower levels of socioeconomic deprivation, although baseline sleep variables were similar between respondents and non-respondents. Around 40% of respondents reported sleep duration less than 7 hours and 49% reported poor sleep quality (Pittsburgh Sleep Quality Index > 5). Approximately one-quarter (25.2%) met criteria for at least one operationally defined sleep disorder, with insomnia being the most common (14.4%) followed by obstructive sleep apnoea (8.0%), restless legs syndrome (4.1%), and frequent nightmares (3.7%). Sleep disorders were associated with higher levels of anxiety, depression, fatigue, and cognitive complaints. Conclusions: Poor sleep quality and operationally defined sleep disorders are common in the UK Biobank cohort. Sleep questionnaire data can now be integrated with a range of biomedical information to advance understanding of sleep. Statement of significance: A comprehensive sleep questionnaire was introduced to the UK Biobank, with over 185,000 participants providing data. Overall, respondents reported relatively poor sleep quality; 40% reported sleep duration less than 7 hours, and 25% met criteria for at least one sleep disorder. Enhanced assessment of sleep in UK Biobank now enables integration with extensive biomedical data, including genetic, wearable, imaging, lifestyle, biomarker, and electronic health record data, offering opportunities to investigate the biological and environmental factors that influence sleep and circadian systems, and their impact on health.
Open AccessSleep and circadian health in the UK Biobank: Report on the 2023 sleep questionnaire enhancement
Study Objectives: Our study introduced the 2023 UK Biobank sleep questionnaire and described variation in sleep health dimensions and prevalence of disordered sleep. Methods: A questionnaire comprising validated measures and bespoke items was developed to capture key self-reported domains of sleep health and symptoms of sleep disorders. We quantified cohort prevalence of operationally defined sleep disorders and assessed patterning of sleep health dimensions across key sociodemographic and clinically relevant variables. Results: 327,752 individuals were invited of whom 185,056 (56.5%) completed at least one module and were included in the analysis. Respondents were predominately from a White ethnic background (96.8%), had a mean age of 69.9 (SD, 7.5) years, 57.9% were female, and 25.5% were in employment. Compared to non-respondents, respondents were more likely to be female, tended to be better educated, healthier, and exhibit lower levels of socioeconomic deprivation, although baseline sleep variables were similar between respondents and non-respondents. Around 40% of respondents reported sleep duration less than 7 hours and 49% reported poor sleep quality (Pittsburgh Sleep Quality Index > 5). Approximately one-quarter (25.2%) met criteria for at least one operationally defined sleep disorder, with insomnia being the most common (14.4%) followed by obstructive sleep apnoea (8.0%), restless legs syndrome (4.1%), and frequent nightmares (3.7%). Sleep disorders were associated with higher levels of anxiety, depression, fatigue, and cognitive complaints. Conclusions: Poor sleep quality and operationally defined sleep disorders are common in the UK Biobank cohort. Sleep questionnaire data can now be integrated with a range of biomedical information to advance understanding of sleep. Statement of significance: A comprehensive sleep questionnaire was introduced to the UK Biobank, with over 185,000 participants providing data. Overall, respondents reported relatively poor sleep quality; 40% reported sleep duration less than 7 hours, and 25% met criteria for at least one sleep disorder. Enhanced assessment of sleep in UK Biobank now enables integration with extensive biomedical data, including genetic, wearable, imaging, lifestyle, biomarker, and electronic health record data, offering opportunities to investigate the biological and environmental factors that influence sleep and circadian systems, and their impact on health.
- Open Access
- 17 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
The Effectiveness of Digital Cognitive Behavioral Therapy to Treat Insomnia Disorder in US Adults: Nationwide Decentralized Randomized Controlled Trial (Preprint)
BACKGROUND Cognitive behavioral therapy (CBT) is recommended as the first-line treatment for insomnia; however, few patients have access to it. A new class of Food and Drug Administration (FDA)–regulated digital CBT treatments has the potential to address this unmet need. These treatments are ordered or prescribed by health care providers and are fully automated, delivering CBT directly to patients without human coaches. This trial builds upon promising earlier digital cognitive behavioral therapy for insomnia (CBT-I) research by using a decentralized design to recruit a sample with greater representation of the US general population, including individuals from lower socioeconomic status groups who often face greater barriers to care. OBJECTIVE This decentralized trial evaluated the effectiveness of a fully automated digital CBT-I program (SleepioRx) for treating insomnia disorder compared with online sleep hygiene education (SHE) in a sample of participants recruited from across the United States. METHODS A decentralized, parallel-group randomized controlled trial was conducted between November 2022 and August 2023. Participants were recruited nationally from across the United States, and a total of 336 adults aged 22 and older, diagnosed with the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) insomnia disorder via structured clinical interview, were allocated 1:1 to either digital CBT-I (SleepioRx) or online SHE. The primary end points were insomnia severity, assessed using the Insomnia Severity Index (ISI), and sleep diary measures of sleep onset latency (SOL) and wake after sleep onset (WASO) at 10 weeks, with follow-up assessments at 16 and 24 weeks postrandomization. RESULTS Compared with SHE, SleepioRx showed statistically and clinically significant improvements on the ISI at posttreatment (10 weeks; Cohen d=0.60, P<.001), with effects sustained at follow-up (16 weeks; d=0.65, P<.001; and 24 weeks, d=0.77, P<.001). SleepioRx led to significant reductions in WASO at all time points (10 weeks, P=.003; 16 and 24 weeks, P<.001); however, effects on SOL were not statistically significant at an adjusted α (10 weeks, P=.01; 16 weeks, P=.07; 24 weeks, P=.27). SleepioRx participants had 2.5 times (odds ratio 2.52; P<.001, 99% CI 1.33-4.75) and 5.8 times (odds ratio 5.78; P<.001, 99% CI 2.11-15.84) greater odds of response and remission at week 10, respectively, with statistically and clinically significant differences in rates sustained at follow-up assessments (P<.001). SleepioRx also demonstrated sustained improvements in secondary sleep and broader mental health outcomes. CONCLUSIONS The results of this trial demonstrate the effectiveness of digital CBT-I (SleepioRx) for treating insomnia, with gains sustained at 6 months, and support the FDA authorization of SleepioRx for the treatment of insomnia disorder. These findings underscore the potential of a new class of FDA-authorized, fully automated digital treatments to provide first-line, guideline-recommended CBT at scale. Efforts should now focus on expanding access to these evidence-based treatments. CLINICALTRIAL ClinicalTrials.gov NCT05541055; https://clinicaltrials.gov/ct2/show/NCT05541055
- 17 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Effectiveness of Digital Cognitive Behavioral Therapy to Treat Insomnia Disorder in US Adults: Nationwide Decentralized Randomized Controlled Trial (Preprint)
BACKGROUND Cognitive behavioral therapy (CBT) is recommended as the first-line treatment for insomnia; however, few patients have access to it. A new class of Food and Drug Administration (FDA)–regulated digital CBT treatments has the potential to address this unmet need. These treatments are ordered or prescribed by health care providers and are fully automated, delivering CBT directly to patients without human coaches. This trial builds upon promising earlier digital cognitive behavioral therapy for insomnia (CBT-I) research by using a decentralized design to recruit a sample with greater representation of the US general population, including individuals from lower socioeconomic status groups who often face greater barriers to care. OBJECTIVE This decentralized trial evaluated the effectiveness of a fully automated digital CBT-I program (SleepioRx) for treating insomnia disorder compared with online sleep hygiene education (SHE) in a sample of participants recruited from across the United States. METHODS A decentralized, parallel-group randomized controlled trial was conducted between November 2022 and August 2023. Participants were recruited nationally from across the United States, and a total of 336 adults aged 22 and older, diagnosed with the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) insomnia disorder via structured clinical interview, were allocated 1:1 to either digital CBT-I (SleepioRx) or online SHE. The primary end points were insomnia severity, assessed using the Insomnia Severity Index (ISI), and sleep diary measures of sleep onset latency (SOL) and wake after sleep onset (WASO) at 10 weeks, with follow-up assessments at 16 and 24 weeks postrandomization. RESULTS Compared with SHE, SleepioRx showed statistically and clinically significant improvements on the ISI at posttreatment (10 weeks; Cohen d=0.60, P<.001), with effects sustained at follow-up (16 weeks; d=0.65, P<.001; and 24 weeks, d=0.77, P<.001). SleepioRx led to significant reductions in WASO at all time points (10 weeks, P=.003; 16 and 24 weeks, P<.001); however, effects on SOL were not statistically significant at an adjusted α (10 weeks, P=.01; 16 weeks, P=.07; 24 weeks, P=.27). SleepioRx participants had 2.5 times (odds ratio 2.52; P<.001, 99% CI 1.33-4.75) and 5.8 times (odds ratio 5.78; P<.001, 99% CI 2.11-15.84) greater odds of response and remission at week 10, respectively, with statistically and clinically significant differences in rates sustained at follow-up assessments (P<.001). SleepioRx also demonstrated sustained improvements in secondary sleep and broader mental health outcomes. CONCLUSIONS The results of this trial demonstrate the effectiveness of digital CBT-I (SleepioRx) for treating insomnia, with gains sustained at 6 months, and support the FDA authorization of SleepioRx for the treatment of insomnia disorder. These findings underscore the potential of a new class of FDA-authorized, fully automated digital treatments to provide first-line, guideline-recommended CBT at scale. Efforts should now focus on expanding access to these evidence-based treatments. CLINICALTRIAL ClinicalTrials.gov NCT05541055; https://clinicaltrials.gov/ct2/show/NCT05541055
- Open Access
- 20 August 2025
- Published by Wiley in Journal of Sleep Research
- Vol. 35 (2) , e70181
Lucid Dreaming: Not Just Awareness, but Agency
During lucid dreaming (LD), dreamers are aware that they are dreaming and may be able to influence the oneiric content. There has been recent debate about the relative importance of the ability to influence the dream and having agency over the pure awareness of dreaming. To underline this, we examined the associations of lucid dreams without agency (LD−Ag) and lucid dreams with agency (LD + Ag) to sleep and mental health problems and long COVID during the pandemic. We collected data in 16 countries on four continents from May to December 2021 on 10,715 subjects. Logistic regression was performed to predict LD−Ag and LD + Ag, with a sample of 8133 participants. We found that 30% of the participants frequently knew they were dreaming during the pandemic. About half of those (17%) reported that they could influence their dreams. Female gender and anxiety symptoms were negatively associated with LD + Ag. Dream recall, nightmares, insomnia, dream enactment behaviour (DEB), sleep vocalisation, short and long COVID and PTSD were positively associated with LD + Ag. Old age, dream recall, nightmares and anxiety symptoms were positively associated with LD−Ag, while short sleep length, being an evening type, and short COVID were negatively associated with LD−Ag. The different associations for LD−Ag and LD + Ag suggest that they may be distinct sleep states. This is also the first study to show that both COVID‐19 and long COVID are associated with LD.
- 20 August 2025
- Published by Wiley in Journal of Sleep Research
- Vol. 35 (2) , e70181
Open AccessLucid Dreaming: Not Just Awareness, but Agency
During lucid dreaming (LD), dreamers are aware that they are dreaming and may be able to influence the oneiric content. There has been recent debate about the relative importance of the ability to influence the dream and having agency over the pure awareness of dreaming. To underline this, we examined the associations of lucid dreams without agency (LD−Ag) and lucid dreams with agency (LD + Ag) to sleep and mental health problems and long COVID during the pandemic. We collected data in 16 countries on four continents from May to December 2021 on 10,715 subjects. Logistic regression was performed to predict LD−Ag and LD + Ag, with a sample of 8133 participants. We found that 30% of the participants frequently knew they were dreaming during the pandemic. About half of those (17%) reported that they could influence their dreams. Female gender and anxiety symptoms were negatively associated with LD + Ag. Dream recall, nightmares, insomnia, dream enactment behaviour (DEB), sleep vocalisation, short and long COVID and PTSD were positively associated with LD + Ag. Old age, dream recall, nightmares and anxiety symptoms were positively associated with LD−Ag, while short sleep length, being an evening type, and short COVID were negatively associated with LD−Ag. The different associations for LD−Ag and LD + Ag suggest that they may be distinct sleep states. This is also the first study to show that both COVID‐19 and long COVID are associated with LD.